Shares of AbbVie (NYSE:ABBV) are on the rebound after a sell-off in early February on concerns about the pending decision by an advisory panel to the Food and Drug
...
The iShares Nasdaq Biotechnology ETF
(NASDAQ:IBB), which tracks the Nasdaq Biotechnology Index (NASDAQ:NBI), has been in free fall since the beginning of the
year ...
Sanofi [NYSE:
SNY] and Regeneron Pharmaceuticals [NASDAQ:REGN] said on Sunday that their results from a pivotal Phase 3 study,
SARIL-RA-TARGET, of
sarilumab ...
Shares of AbbVie
[NYSE:ABBV] have surged 38.13% from the low of $45.45 a share on October 22, to close on Thursday at $62.78 a share. The company reported its third-quarter
...
Wall Street is more bullish on Allergan PLC [NYSE:AGN] as the company is on a M&A shopping spree and is selling its slow growth and low margin business. Over the past two
...
Shares of Regeneron Pharmaceuticals
[NASDAQ:REGN] surged 9.32% to a record high of $605.93 per share on August 4 after the company announced a blowout earnings report
...
Gilead Sciences
[NASDAQ:GILD] just announced its blowout second-quarter ended June 2015 revenues of $8.24 billion, compared to $6.54 billion in 2014. Net income for the
...
In the second quarter 2015, AbbVie [NYSE:ABBV] reported worldwide sales of $5.48 billion, up 11.1% year-over-year. On an operational basis, sales increased 19.4%, excluding
...
